H.C. Wainwright lowered the firm’s price target on Clearside Biomedical (CLSD) to $5 from $6 and keeps a Buy rating on the shares following the Q1 report. The firm’s estimated market value of the company remains unchanged, but the projected shares outstanding have increased.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical Reports Q1 2025 Financial Progress
- Clearside Biomedical: Undervalued Opportunity with Strategic Partnerships and Promising CLS-AX Advancements
- Clearside Biomedical reports Q1 EPS (11c), consensus (11c)
- Clearside Biomedical announces six presentations related to CLS-AX
- Buy Rating for Clearside Biomedical Backed by Promising Trial Results and FDA Alignment